TY - JOUR
T1 - COVID-19 and Alzheimer's Disease
AU - Gambino, Caterina Maria
AU - Giglio, Rosaria Vincenza
AU - Lo Sasso, Bruna
AU - Agnello, Luisa
AU - Bivona, Giulia
AU - Ciaccio, Marcello
AU - Scazzone, Concetta
AU - Piccoli, Tommaso
AU - Ciaccio, Marcello
AU - Lo Sasso, Bruna
PY - 2021
Y1 - 2021
N2 - The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop neurological symptoms, including confusion, headache, and hypogeusia/ageusia. However, long-term neurological consequences have received little interest compared to respiratory, cardiovascular, and renal manifestations. Several mechanisms have been proposed to explain the potential SARS-CoV-2 neurological injury that could lead to the development of neurodegenerative diseases, including Alzheimer's Disease (AD). A mutualistic relationship between AD and COVID-19 seems to exist. On the one hand, COVID-19 patients seem to be more prone to developing AD. On the other hand, AD patients could be more susceptible to severe COVID-19. In this review, we sought to provide an overview on the relationship between AD and COVID-19, focusing on the potential role of biomarkers, which could represent precious tool for early identification of COVID-19 patients at high risk of developing AD.
AB - The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop neurological symptoms, including confusion, headache, and hypogeusia/ageusia. However, long-term neurological consequences have received little interest compared to respiratory, cardiovascular, and renal manifestations. Several mechanisms have been proposed to explain the potential SARS-CoV-2 neurological injury that could lead to the development of neurodegenerative diseases, including Alzheimer's Disease (AD). A mutualistic relationship between AD and COVID-19 seems to exist. On the one hand, COVID-19 patients seem to be more prone to developing AD. On the other hand, AD patients could be more susceptible to severe COVID-19. In this review, we sought to provide an overview on the relationship between AD and COVID-19, focusing on the potential role of biomarkers, which could represent precious tool for early identification of COVID-19 patients at high risk of developing AD.
UR - http://hdl.handle.net/10447/486997
UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997244/
M3 - Article
SN - 2076-3425
VL - 11
SP - 1
EP - 10
JO - Brain Sciences
JF - Brain Sciences
ER -